Trial Profile

A phase 1 trial evaluating MB-109 (combination of MB-101 (IL13R2targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus)) for the treatment of recurrent glioblastoma (rGBM)

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 13 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Mar 2024 According to Mustang Bio media release, the company evaluating plans to initiate this trial and request orphan drug designation for GBM, subject to resource allocation, in 2024.
26 Oct 2023 According to Mustang Bio media release, the U.S. Food and Drug Administration (FDA) has accepted the IND application of MB-109 for the treatment of recurrent glioblastoma (GBM) and high-grade astrocytoma.
26 Oct 2023 According to Mustang Bio media release, this trial is expected to begin enrolling patients in 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com